A randomized, controlled trial comparing insulin lispro with human soluble insulin in patients with Type 1 diabetes on intensified insulin therapy. The UK Trial Group

What Was Tested

This randomized controlled trial paper looks at Insulin Lispro.

Despite considerable experience with insulin lispro, few blinded comparisons with soluble insulin are available.

This study compared insulin lispro with human soluble insulin in patients with Type 1 diabetes mellitus on multiple injection therapy who inject shortly before meals.

Who Took Part

By PubMed's age tags, the people studied were teenagers, adults and middle-aged adults, both men and women.

Glucose control, frequency of hypoglycaemia and patient preference were examined in the course of a prospective, randomized, double-blind, crossover comparison, with a 6-week run-in period and 12 weeks on each therapy.

The main outcome measures were self-monitored blood glucose profiles, glycated haemoglobin, frequency of hypoglycaemic episodes, patient satisfaction and well-being and patient preference.

How the Study Was Run

The design is described as randomized, double-blind and crossover.

Because people in this Insulin Lispro study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the participants and researchers unaware of who received Insulin Lispro.

In the crossover set-up each of the participants took both Insulin Lispro and the comparison in turn, acting as their own control.

What Was Measured

PubMed files the paper under topics including Blood Glucose, Diabetes Mellitus, Type 1, Diet, Food, Hypoglycemia, Hypoglycemic Agents and Insulin.

What This Means in Plain Language

The paper is a randomized, double-blind and crossover study of Insulin Lispro.

The abstract goes on to report its results in about 8 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2000 (Diabetic medicine : a journal of the British Diabetic Association), a journal based in England.

More context: the Insulin Lispro compound page, all human trials.